Sona Nanotech to hold investor webinar March 18

Executive Summary

• Sona Nanotech Inc. is hosting an investor webinar on March 18, 2026, to present follow-up data from its first-in-human study of Targeted Hyperthermia therapy (THT) for late-stage melanoma.
• The study involved 10 patients who had failed standard-of-care immunotherapy protocols. Results showed an 80% clinical response rate (CRR) and complete responses in 6 out of 10 treated and biopsied tumors.
• Key findings include evidence of an "abscopal effect," where THT treatments generated clinical responses in secondary, untreated tumors in one study patient.

Key Details

• Webinar Details: Scheduled for Wednesday, March 18, 2026, at 3:30 p.m. ET. A recording will be available on the company website.
• Study Population: 10 late-stage melanoma patients who had failed on standard-of-care immunotherapy protocols.
• Primary Objective: Assess safety, tolerability, and efficacy of THT as a monotherapy in humans.
• Clinical Response Rates:
  • 80% Clinical Response Rate (CRR) observed in treated tumors.
  • Complete responses seen in 6 out of 10 treated and biopsied tumors.
  • 60% of treated, biopsied tumors cleared in only two weeks.
• Abscopal Effect: Evidence presented that THT treatments generated a clinical response in secondary, untreated tumors in a study patient.
• Key Speakers:
  • Dr. Carlos Rojas (Principal Investigator, Centro de Investigacion Clinica, Bradford Hill)
  • David Regan (CEO, Sona Nanotech Inc.)
  • Dr. Carman Giacomantonio (Chief Medical Officer, Sona Nanotech Inc.)

Notable Quotes

• David Regan, CEO: "We are excited to be able to share our perspectives on some follow-up data from our first-in-human study from the principal investigator. While the study was intended to assess THT's safety, tolerability and ability to prime tumours for further treatment, THT given as a monotherapy treatment demonstrated in an astounding 80 per cent clinical response rate (CRR), with 60 per cent of treated, biopsied tumours cleared in only two weeks. In particular, evidence of an abscopal effect will be discussed with an opportunity for participants to question the study's principal investigator."